Peripheral Edema News and Research

RSS
Global burden of heart failure: prevalence, incidence, and risk factors unveiled

Global burden of heart failure: prevalence, incidence, and risk factors unveiled

Study finds accounting for sex improves precision and prognostic performance of CMR biomarkers for heart failure

Study finds accounting for sex improves precision and prognostic performance of CMR biomarkers for heart failure

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

The burden of Clostridioides difficile infections in the United States

The burden of Clostridioides difficile infections in the United States

COVID-19 vaccination humoral immune response in individuals with diabetes

COVID-19 vaccination humoral immune response in individuals with diabetes

Novel antibody-drug conjugate shows 29% response rate in rare blood cancer

Novel antibody-drug conjugate shows 29% response rate in rare blood cancer

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

UPV researchers develop new methodology to monitor patients with glioblastoma

UPV researchers develop new methodology to monitor patients with glioblastoma

New drug Aliskiren shows promise for heart failure patients

New drug Aliskiren shows promise for heart failure patients

FDA grants approval for generic versions of Lyrica

FDA grants approval for generic versions of Lyrica

FDA approves new treatment for rare disease of the bone marrow and blood

FDA approves new treatment for rare disease of the bone marrow and blood

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

FDA approves Cassipa sublingual film for maintenance treatment of opioid dependence

FDA approves Cassipa sublingual film for maintenance treatment of opioid dependence

Alnylam’s patisiran receives positive opinion from CHMP for treating hATTR amyloidosis

Alnylam’s patisiran receives positive opinion from CHMP for treating hATTR amyloidosis

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

FDA approves first drug for treatment of adult AML patients with specific genetic mutation

FDA approves first drug for treatment of adult AML patients with specific genetic mutation

Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications

Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.